{"id":3806,"date":"2025-03-31T18:11:50","date_gmt":"2025-03-31T18:11:50","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/captopril-txt\/"},"modified":"2025-03-31T18:11:50","modified_gmt":"2025-03-31T18:11:50","slug":"captopril-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/captopril-txt\/","title":{"rendered":"Captopril.txt"},"content":{"rendered":"

Captopril<\/h1>\n

CLINICAL USE <\/H3>
\nAngiotensin-converting enzyme inhibitor:<\/p>\n
  • Hypertension\n
  • Heart failure\n
  • Post myocardial infarction\n
  • Diabetic nephropathy

    DOSE IN NORMAL RENAL FUNCTION <\/H3>6.25\u201350 mg 2\u20133 times daily\n
  • Diabetic nephropathy: 75\u2013100 mg daily in divided doses

    PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :217.3<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :25\u201330<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 40\u201350<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :2<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :2\u20133\/21\u201332

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Start low \u2013 adjust according to response
  • 10 to 20 &nbsp &nbsp : Start low \u2013 adjust according to response
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Start low \u2013 adjust according to response

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL\/min
  • HDF\/high flux &nbsp :Dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Dialysed. Dose as in GFR=10\u201320 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Anaesthetics: enhanced hypotensive effect cinAnalgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs\n
  • Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity\n
  • Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics\n
  • Epoetin: increased risk of hyperkalaemia; antagonism of hypotensive effect\n
  • Lithium: reduced excretion, possibility of enhanced lithium toxicity\n
  • Potassium salts: increased risk of hyperkalaemia.\n
  • Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity

    ADMINISTRATION <\/H3>

    Reconstition<\/H4> \u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4> \u2013

    Comments<\/H4>Tablets may be dispersed in water

    OTHER INFORMATION <\/H4>A\n
  • dverse reactions, especially hyperkalaemia, are more common in patients with renal impairment\n
  • Effective sub-lingually in emergencies As renal function declines a hepatic elimination route for captopril becomes increasingly more significant\n
  • Renal failure has been reported in association with ACE inhibitors in patients with renal artery stenosis, post renal transplant, or in those with congestive heart failure\n
  • A high incidence of anaphylactoid reactions has been reported in patients dialysed with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor \u2013 this combination should therefore be avoided\n
  • Close monitoring of renal function during therapy is necessary in those with renal insufficiency.
    \n","protected":false},"excerpt":{"rendered":"

    Captopril CLINICAL USE Angiotensin-converting enzyme inhibitor: Hypertension Heart failure Post<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3806","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3806","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3806"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3806\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3806"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3806"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}